Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
Sponsor study identifier
observational
30,000
1 country
1
Study Start
May 1, 2011
Actual (reported)Primary Completion
October 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 1, 2036
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 1, 2036
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 1, 2011
Actual (reported)June 10, 2011
Actual (reported)June 14, 2011
Actual (reported)October 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 1, 2036
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Number of Participants with major adverse events
Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.
5 years
blood routine, glucose and lipid profile; ECG;
5 years
serum adiponectin concentration, activity and isoforms
5 years
volunteer
Xijing Hospital
Xi'an, Shaanxi, 710032, China
Gao C, Zhao S, Lian K, Mi B, Si R, Tan Z, Fu F, Wang S, Wang R, Ma X, Tao L. C1q/TNF-related protein 3 (CTRP3) and 9 (CTRP9) concentrations are decreased in patients with heart failure and are associated with increased morbidity and mortality. BMC Cardiovasc Disord. 2019 Jun 10;19(1):139. doi: 10.1186/s12872-019-1117-0.
blood
First Submitted
June 10, 2011
First Posted
June 14, 2011
Study Start
May 1, 2011
Actual (reported)Primary Completion
October 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Long Term Follow-up of Autologous Bone Marrow Mononuclear Cells Therapy in STEMI
Contact the study team to confirm eligibility.
Study Completion
October 1, 2036
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 7, 2025
Record last verified: 2025-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: